Early Administration of Heparin at FMC for PPCI of STEMI Patients

• Status: Not yet recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients. However, the priority of use of hepairn in first medical contact or in Cathlab has yet studied. Previous study revealed early use of antithrombotic drugs could improve patient's survival. Here we supposed that use of heparin at first medical contact could the TIMI flow 3 grade ratio in STEMI patients and improve patient's survival and/or reduce MACE rather than in Cathlab.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Renmin Hospital of Wuhan University
• Collaborators: Jiangxi Provincial People's Hopital; The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture; The First Affiliated Hospital of Dalian Medical University; The First College of Clinical Medical Science, China Three Gorges University; Wuhan Central Hospital; Xiangyang Central Hospital
• Treatments: Calcium heparin; Heparin

Criteria

Inclusion Criteria:

• STEMI patient; Symptom onset in 12 hours; Intended to perform PPCI

Exclusion Criteria:

• Active bleeding; Life expectancy less than 1 year; History of heparin-induced thrombocytopenia; Mechanical complication of MI (VSR, acute MR); History of PCI or CABG; On Coagulation drugs